Krebs Biochemicals and Industries Limited Stock Price Today (NSE: KREBSBIO)
Fundamental Score
Krebs Biochemicals and Industries Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Krebs Biochemicals and Industries Limited share price today is ₹56.86, up +1.14% on NSE/BSE as of 22 September 2026. Krebs Biochemicals and Industries Limited (KREBSBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹122.59 (Cr). The 52-week high for KREBSBIO share price is ₹81.80 and the 52-week low is ₹38.33.
Krebs Biochemicals and Industries Limited Share Price Chart — NSE/BSE Historical Performance
Krebs Biochemicals and Industries Limited share price chart: 5.08% return over the past month. 52-week high ₹81.80, 52-week low ₹38.33.
Krebs Biochemicals and Industries Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹56.45 | ₹58.90 | ₹55.40 | ₹56.22 | 7.35K (Cr) | |
| ₹56.94 | ₹62.80 | ₹55.80 | ₹57.31 | 54.50K (Cr) | |
| ₹55.65 | ₹57.60 | ₹55.10 | ₹55.48 | 4.12K (Cr) | |
| ₹55.50 | ₹57.80 | ₹54.66 | ₹55.65 | 5.06K (Cr) | |
| ₹58.50 | ₹59.50 | ₹56.03 | ₹56.27 | 7.98K (Cr) | |
| ₹62.89 | ₹62.89 | ₹57.07 | ₹58.72 | 8.04K (Cr) | |
| ₹61.00 | ₹64.50 | ₹59.99 | ₹61.47 | 79.98K (Cr) | |
| ₹57.40 | ₹66.66 | ₹57.40 | ₹60.14 | 1.33L (Cr) | |
| ₹56.00 | ₹58.00 | ₹55.68 | ₹56.73 | 3.19K (Cr) | |
| ₹55.14 | ₹57.72 | ₹54.26 | ₹55.99 | 3.61K (Cr) |
Krebs Biochemicals and Industries Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹56.29 | ₹66.66 | ₹53.65 | ₹56.22 | -0.12% | |
| ₹53.11 | ₹62.00 | ₹52.86 | ₹56.29 | +5.99% | |
| ₹61.97 | ₹61.97 | ₹50.81 | ₹53.65 | -13.43% | |
| ₹64.00 | ₹71.50 | ₹59.10 | ₹60.13 | -6.05% | |
| ₹59.38 | ₹71.25 | ₹54.32 | ₹65.16 | +9.73% | |
| ₹43.00 | ₹68.58 | ₹40.00 | ₹59.67 | +38.77% | |
| ₹56.30 | ₹56.98 | ₹38.33 | ₹39.75 | -29.40% | |
| ₹59.78 | ₹62.80 | ₹54.00 | ₹57.04 | -4.58% | |
| ₹71.80 | ₹73.01 | ₹53.05 | ₹58.82 | -18.08% | |
| ₹67.40 | ₹76.85 | ₹63.60 | ₹69.04 | +2.43% | |
| ₹73.00 | ₹73.00 | ₹64.16 | ₹67.40 | -7.67% | |
| ₹71.80 | ₹74.70 | ₹65.55 | ₹69.04 | -3.84% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Krebs Biochemicals and Industries Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Krebs Biochemicals and Industries Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KREBSBIO across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Revenue Growth (27.42%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: -1.38)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Suboptimal ROCE (-17.02%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-31.63%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-53.33%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-15.07% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-1.39x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.09)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-98.66 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.50%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Krebs Biochemicals and Industries Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Krebs Biochemicals and Industries Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Krebs Biochemicals and Industries LimitedKrebs Biochemic...Selected✓ KREBSBIO • 524518 | 27/100 | ₹56.86₹57 | ₹122.59₹122.59 | — — | — — | -17.02%Poor -17.02% Poor | -1.38Excellent -1.4 Excellent | 7.01%Good 7.01% Good | -15.07%Poor -15.07% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Krebs Biochemicals and Industries Limited Quarterly Performance
Latest quarterly metrics for KREBSBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
27.42%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-53.33%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-15.07%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
7.01%
Compounded annual net profit growth over 5 years
Krebs Biochemicals and Industries Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KREBSBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Krebs Biochemicals and Industries Limited Financial Statements
Annual income statement, balance sheet and cash flow for Krebs Biochemicals and Industries Limited (KREBSBIO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Krebs Biochemicals and Industries Limited
About KREBSBIO (Krebs Biochemicals and Industries Limited)
Krebs Biochemicals & Industries Limited is a pioneering force in the pharmaceutical landscape of India, dedicated to the intricate art of crafting active pharmaceutical ingredients... (APIs). With a resolute commitment to advancing healthcare, KREBSBIO meticulously engineers biotech processes that transcend the conventional, finding vital applications not only in medicine but also in the realms of agriculture and diverse industrial sectors. The company's steadfast dedication to research and development fuels the creation of groundbreaking solutions that address critical health challenges and improve the quality of life for individuals worldwide. At the heart of KREBSBIO's operations lies a diverse portfolio of specialized APIs, each meticulously crafted to meet the exacting demands of the pharmaceutical industry. Renowned for its expertise in steroid intermediates and anti-cholesterol treatments, KREBSBIO produces essential ingredients such as androstenedione, lovastatin, and simvastatin, which serve as building blocks for life-saving medications. These high-quality APIs play a pivotal role in the formulation of pharmaceuticals that combat cardiovascular diseases and hormonal imbalances, empowering healthcare professionals to deliver effective treatments. Driven by an unwavering pursuit of innovation, KREBSBIO continues to expand its horizons, diligently developing a range of novel products that address a spectrum of therapeutic needs. The company's research pipeline encompasses a variety of promising APIs, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, each designed to combat specific ailments and enhance patient well-being. By constantly pushing the boundaries of pharmaceutical science, KREBSBIO remains at the forefront of the industry, dedicated to providing cutting-edge solutions that improve global health outcomes.
Company Details
Key Leadership
KREBSBIO Share Price: Frequently Asked Questions
What is the current share price of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited (KREBSBIO) trades at ₹56.86 on NSE and BSE. Market cap ₹122.59 (Cr). Educational data only.
What is the P/E ratio of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has a Bull Run score of 27/100 based on 25+ financial parameters.
Does Krebs Biochemicals and Industries Limited pay dividends?
Krebs Biochemicals and Industries Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has debt-to-equity of -1.38.
Is Krebs Biochemicals and Industries Limited a good investment?
Bull Run gives Krebs Biochemicals and Industries Limited a score of 27/100. This is not investment advice — consult a SEBI-registered advisor.